Key result
Adriamycin and methyl-CCNU combination therapy yielded a 14% objective response rate and an 87-day median survival in patients with unresectable hepatocellular carcinoma.
Why the study?
What is the efficacy, toxicity, and pharmacokinetic profile of Adriamycin and methyl-CCNU combination therapy in patients with unresectable hepatocellular carcinoma?
Population
21 patients with unresectable hepatocellular carcinoma (hepatoma)
Design
Case_series
Authors
Loading...
Suggests modest activity with feasible dosing despite hepatic impairment; leaves open need for randomized trials in unresectable HCC.
What is the efficacy, toxicity, and pharmacokinetic profile of Adriamycin and methyl-CCNU combination therapy in patients with unresectable hepatocellular carcinoma?
In patients with hepatoma, Adriamycin disposition remains normal despite moderate hepatic dysfunction, suggesting that severe dosage adjustments may not be necessary.
Chlebowski et al. (1981) studied unresectable hepatocellular carcinoma (n=21). Adriamycin and methyl-CCNU was evaluated on Objective response frequency. Adriamycin and methyl-CCNU combination therapy yielded a 14% objective response rate and an 87-day median survival in patients with unresectable hepatocellular carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: